Market Research Logo

Chronic Kidney Disease Drugs Market - Global Forecast to 2026

Chronic Kidney Disease Drugs Market - Global Forecast to 2026

Chronic kidney disease can be controlled and prevented from worsening with the help of kidney friendly diet plans and efficiently managing other diseases, which may lead to chronic kidney diseases. For instance, facts such as maintaining a healthy blood pressure, having a low-salt and low-fat diet, control blood sugar, regular exercise, and avoiding smoking and drinking may prevent chronic kidney disease from worsening. Another form of kidney disease is acute kidney disease, which occurs directly due to disorders affecting kidney such as inadequate blood supply and improper urine flow from kidneys. Apart from medication management, other treatment options for end stage renal diseases include dialysis and kidney transplant.
Market Dynamics
The global chronic kidney disease drugs market is driven by factors such as increasing prevalence of chronic kidney disease and high presence of generic drug manufacturers in the market. According to the Centers for Disease Control & Prevention (CDC), around 15% of the adults in the U.S. were estimated to have chronic kidney disease in 2017. Individual government organizations and manufactures are indulged in research and development as well as increasing awareness about chronic kidney diseases, which is fostering growth of the chronic kidney disease drugs market. In March 2018, the Indian Medical Association (IMA) launched chronic kidney disease prevention project to control the epidemic of chronic kidney disease. Continuous requirement of medication coupled with easy availability of drugs is expected to boost growth of chronic kidney disease drugs market over the forecast period. However, absence of novel treatment option and delay in diagnosis of the disease due to vague symptoms are expected to hinder growth of the chronic kidney disease drugs market.
Key features of the study:

  • This report provides in-depth analysis of chronic kidney disease drugs market and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2018–2026), considering 2017 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global chronic kidney disease drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Amgen Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., AstraZeneca Plc, F. Hoffmann-La Roche Ltd., Sanofi S.A., Kissei Pharmaceutical Co. Ltd., AbbVie Inc., GlaxoSmithKline Plc, and Keryx Biopharmaceuticals Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global chronic kidney disease drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the chronic kidney disease drugs market
Detailed Segmentation:
  • Global Chronic Kidney Disease Drugs Market, By Drug Class:
  • ACE Inhibitors
  • B-Blockers
  • Calcium Channel Blockers
  • Diuretics
  • Erythropoiesis-Stimulating Agents (ESAs)
  • Others
  • Global Chronic Kidney Disease Drugs Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Global Chronic Kidney Disease Drugs Market, By Region:
  • North America
  • By Drug Class:
  • ACE Inhibitors
  • B-Blockers
  • Calcium Channel Blockers
  • Diuretics
  • Erythropoiesis-Stimulating Agents (ESAs)
  • Others
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country:
  • U.S.
  • Canada
  • Europe
  • By Drug Class:
  • ACE Inhibitors
  • B-Blockers
  • Calcium Channel Blockers
  • Diuretics
  • Erythropoiesis-Stimulating Agents (ESAs)
  • Others
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country:
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • By Drug Class:
  • ACE Inhibitors
  • B-Blockers
  • Calcium Channel Blockers
  • Diuretics
  • Erythropoiesis-Stimulating Agents (ESAs)
  • Others
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country:
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
  • By Drug Class:
  • ACE Inhibitors
  • B-Blockers
  • Calcium Channel Blockers
  • Diuretics
  • Erythropoiesis-Stimulating Agents (ESAs)
  • Others
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country:
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East
  • By Drug Class:
  • ACE Inhibitors
  • B-Blockers
  • Calcium Channel Blockers
  • Diuretics
  • Erythropoiesis-Stimulating Agents (ESAs)
  • Others
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • By Drug Class:
  • ACE Inhibitors
  • B-Blockers
  • Calcium Channel Blockers
  • Diuretics
  • Erythropoiesis-Stimulating Agents (ESAs)
  • Others
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country:
  • Central Africa
  • South Africa
  • North Africa
  • Company Profiles
  • Amgen, Inc.*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Key Strategies
  • Recent Developments
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer, Inc.
  • AstraZeneca Plc
  • F. Hoffmann La Roche Ltd.
  • Sanofi S.A.
  • Kissei Pharmaceutical Co. Ltd.
  • AbbVie Inc.
  • GlaxoSmithKline Plc
  • Keryx Biopharmaceuticals, Inc.
“*” marked represents similar segmentation in other categories in the respective section.


1. Research Objective and Assumption
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Snippet, By Drug Class
Market Snippet, By Distribution Channel
Market Snippet, By Region
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Restraints
Market Opportunities
Impact Analysis
PEST Analysis
PORTER’s Analysis
Regulatory Scenario
4. Global Chronic Kidney Disease Drugs Market, By Drug Class, 2016–2026 (US$ Mn)
Introduction
Market Share Analysis, 2017 and 2026 (%)
Y-o-Y Growth Analysis, 2017–2026
Segment Trends
ACE Inhibitors
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
B-Blockers
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
Calcium Channel Blockers
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
Diuretics
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
Erythropoiesis-Stimulating Agents (ESAs)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
5. Global Chronic Kidney Disease Drugs Market, By Distribution Channel, 2016–2026 (US$ Mn)
Introduction
Market Share Analysis, 2017 and 2026 (%)
Y-o-Y Growth Analysis, 2016–2026
Segment Trends
Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
6. Global Chronic Kidney Disease Drugs Market, By Regions, 2016–2026 (US$ Mn)
Introduction
Market Share Analysis, By Region, 2017 and 2026 (%)
Y-o-Y Growth Analysis, For Regions, 2017–2026
North America
Market Size and Forecast, By Drug Class, 2016–2026 (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2016–2026 (US$ Mn)
Market Size and Forecast, By Country, 2016–2026 (US$ Mn)
U.S.
Canada
Europe
Market Size and Forecast, By Drug Class, 2016–2026 (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2016–2026 (US$ Mn)
Market Size and Forecast, By Country, 2016–2026 (US$ Mn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
Market Size and Forecast, By Drug Class, 2016–2026 (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2016–2026 (US$ Mn)
Market Size and Forecast, By Country, 2016–2026 (US$ Mn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of APAC
Latin America
Market Size and Forecast, By Drug Class, 2016–2026 (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2016–2026 (US$ Mn)
Market Size and Forecast, By Country, 2016–2026 (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Africa
Market Size and Forecast, By Drug Class, 2016–2026 (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2016–2026 (US$ Mn)
Market Size and Forecast, By Country, 2016–2026 (US$ Mn)
Central Africa
South Africa
North Africa
Middle East
Market Size and Forecast, By Drug Class, 2016–2026 (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2016–2026 (US$ Mn)
Market Size and Forecast, By Country, 2016–2026 (US$ Mn)
GCC
Israel
Rest of Middle East
7. Competitive Landscape
Company Profiles
Amgen, Inc.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Teva Pharmaceutical Industries Ltd.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Pfizer, Inc.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
AstraZeneca Plc
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
F. Hoffman La Roche Ltd.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Sanofi S.A.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Kissei Pharmaceutical Co. Ltd.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
AbbVie, Inc.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
GlaxoSmithKline Plc
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Keryx Biopharmaceuticals, Inc.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
8. Section
References
Research Methodology
About us and Sales Contact
*Browse 29 market data tables and 47 figures on "Chronic Kidney Disease Drugs Market - Global forecast to 2026”.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report